AYA.AX Artrya Limited ASX -4.28% pre-market 03 Apr 2026: AI imaging outlook

AYA.AX stock opened the ASX pre-market on 03 Apr 2026 at A$3.13, down -4.28% from yesterday as volume tracked below average. Artrya Limited (AYA.AX) is an Australian medical technology company that sells AI imaging software (Salix) for coronary artery disease detection. The drop follows mixed trading with a day low of A$3.03 and a day high of A$3.40, and recent volatility after a 3-month decline of -34.71%. We review valuation, technicals, Meyka AI grade, and a model forecast to frame the pre-market position for AI stocks investors.

AYA.AX stock: pre-market price action and near-term drivers

AYA.AX stock trades on the ASX at A$3.13 with market capitalisation of A$376678000.00 and 113800000.00 shares outstanding. The share price is below the 50-day average of A$3.31 and above the 200-day average of A$2.80, indicating mixed short-term momentum. Pre-market weakness reflects profit-taking after a strong one-year return of 350.34% and fresh investor focus on revenue traction and clinical adoption.

Financials and valuation: revenue, EPS and key ratios

Artrya reports trailing EPS of -0.17 and a negative PE of -19.47, consistent with a growth-stage medtech. Cash per share stands at 0.61 and book value per share at 0.71, giving a price-to-book of 4.66. Sales remain small versus enterprise value; price-to-sales and EV-to-sales are very high, reflecting early commercialisation and high R&D intensity.

Meyka AI rates AYA.AX with a score out of 100 and forecast

Meyka AI rates AYA.AX with a score out of 100: 63.87 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly price of A$4.36 and a 12-month price of A$7.41. Compared with the current A$3.13, the 3-month model implies +39.30% upside and the 12-month model implies +136.60% upside. Forecasts are model-based projections and not guarantees.

Technical outlook and trading setup for AI stocks

Momentum indicators show neutral bias: RSI 53.19, MACD histogram 0.06, and ADX 18.36 (no clear trend). Price sits near the Bollinger middle band (A$3.12) with ATR 0.26, so intraday ranges remain modest. Traders should watch support at A$3.03 and resistance near A$3.62 (BB upper) for short-term entries or exits.

Sector context: Healthcare AI peers and relative valuation

Artrya sits in Healthcare, Medical – Healthcare Information Services. The sector average PE is 27.30 and average PB is 4.18. Artrya’s PB of 4.66 and cash-rich balance sheet (current ratio 37.11) show stronger liquidity but lower revenue scale. Investors should compare commercial traction and regulatory approvals among AI imaging peers when assessing valuation and adoption risks.

Risks and opportunities for Artrya Limited

Key opportunities include faster hospital rollouts of Salix and reimbursement wins that could drive revenue. Major risks include slow commercial adoption, lengthy clinical validation cycles, and high SGA and R&D spend (SG&A to revenue 486.34%, R&D to revenue 84.34%). Capital-light debt levels (debt-to-equity 0.01) reduce refinancing risk but do not offset execution risk.

Final Thoughts

Key takeaways for AYA.AX stock on 03 Apr 2026: Artrya trades at A$3.13 in the ASX pre-market after a small pullback that follows strong multi-year gains. Valuation metrics show a growth-stage company with negative EPS (-0.17) and a high price-to-book (4.66). Meyka AI rates AYA.AX 63.87/100 (Grade B, HOLD) and flags a modelled 12‑month forecast of A$7.41, implying +136.60% from today’s price, and a 3-month target of A$4.36 (+39.30%). Technicals are neutral, with RSI 53.19 and support at A$3.03. Investors seeking AI healthcare exposure should weigh the upside from product adoption against execution and commercialisation risks. Meyka AI’s data-driven view is one input; forecasts are model outputs and not guarantees. For company details see the Artrya website and ASX company page. Access our real-time tools at Meyka AI AYA.AX page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.